国际医学放射学杂志2016，Vol.39Issue(3)：281-284,4.DOI:10.19300/j.2016.Z3719
骨肉瘤新辅助化疗的疗效评价
Assessment of the response to neoadjuvant chemotherapy in osteosarcoma
张云 1崔建岭1
作者信息
- 1. 河北医科大学附属第三医院CT室，石家庄 050051
- 折叠
摘要
Abstract
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with an estimated incidence of 3 cases/million population per year. The prognosis is very poor because of pulmonary metastasis.With neoadjuvant chemotherapy, the therapeutic efficacy of osteosarcoma has been greatly improved since 1970s, five-year disease-free survival rate has been raised from less than 20%to 60%-70%, and limb salvage rate has been increased to more than 80%. The neoadjuvant chemotherapy has been shown to be the most significantly prognostic factor in patients with osteosarcoma. Thus, neoadjuvant chemotherapy evaluation methods are becoming a hot topic. This review summarized the evaluation methods of neoadjvant chemotherapy in recent years.关键词
骨肉瘤/新辅助化疗/评价/坏死率/体积/ADC值Key words
Osteosarcoma/Neoadjuvant chemotherapy/Evaluation/Necrosis rate/Volume/ADC value引用本文复制引用
张云,崔建岭..骨肉瘤新辅助化疗的疗效评价[J].国际医学放射学杂志,2016,39(3):281-284,4.
